1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CB4DB01A11E5B0C0002588F6003DDE4F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/scientific-communication-platform-excellence
18
19
2034.204.176.71
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Medical Communication

Scientific Communication Platform Excellence

ID: POP-353


Features:

9 Info Graphics

37 Data Graphics

340+ Metrics

9 Narratives


Pages: 57


Published: 2022


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Scientific communication platforms (SCPs) help lay the groundwork for all medical and scientific communications for a drug/device or therapeutic area. While SCPs serve as an important means to align communications and value messaging across key functional areas, many organizations still lack clear processes to ensure successful development and implementation, and often scientific communication platforms are not utilized as effectively and broadly as intended.

Best Practices, LLC undertook this benchmarking research to help medical communications/publications leaders with SCP development, utilization, management, and evaluation. The study presents current practices around SCP excellence, examining which functions are involved in SCP development and how these platforms are best utilized. This report also delivers benchmarks around SCP format, location, and timing of updates.

Finally, the report highlights best practices and pitfalls encountered by biopharma and medical device companies during the initiation and development of high-impact scientific communication platforms.

Video Brief:


Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Health Care; Consumer Products; Communications; Laboratories


Companies Profiled:
Alkermes; Astellas; AstraZeneca; BELLUS Health; Boehringer Ingelheim; GlaxoSmithKline ; Gossamer Bio; Incyte; Ipsen; Merck; Nobel Biocare; Novartis; Novo Nordisk; OPEN Health; Oxford PharmaGenesis; Pfizer; Pierre Fabre; Sandoz; Spark Therapeutics; Torrent Pharmaceuticals Ltd.; UniQure

Study Snapshot

Best Practices, LLC engaged 21 Medical leaders from 21 pharma companies in this research through a benchmarking survey. Data in this research is further segmented by mid-small vs. large companies to provide in-depth insights.

Key topics covered in this report include:

  • Development of Scientific Communication Platforms
  • Format and Location of Scientific Communication Platforms
  • Timing of Scientific Communication Platform Updates
  • Effectiveness and Faults of Scientific Communication Platforms
  • Scientific Communication Platform Maintenance and Operations
  • Access and Utilization of Scientific Communication Platforms
  • Best Practices and Pitfalls for SCP Implementation

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • SCP Development: Medical Communications/Publications lead SCP development for 71% of participants; the same holds true for a majority of both Large and Mid-Small segments.

  • SCP Utilization: SCP utilization is measured by a majority (61%) through level of incorporation into reactive and proactive materials for FMTs. Large Pharma particularly use this measure (88%) vs. 36% for Mid-Small (of which 36% do not measure).

Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-9
II.
Participant DemographicsPg. 10-12
III.
SCP DevelopmentPg. 13-25
IV.
SCP Format, Location and UpdatingPg. 26-34
V.
SCP Effectiveness and FaultsPg. 35-38
VI.
SCP OperationsPg. 39-43
VII.
SCP Access and UtilizationPg. 44-50
VIII.
SCP Best Practices and PitfallsPg. 51-56
IX.
About Best Practices, LLCPg. 57

    List of Charts & Exhibits

    I. SCP Development

    • Function(s) leading the development of scientific communication platforms (SCP) – Total benchmark class
    • Function(s) leading the development of scientific communication platforms (SCP) – Mid-small companies vs. Large companies
    • Approach taken for SCP development – Total benchmark class
    • Approach taken for SCP development – Mid-small companies vs. Large companies
    • Medical group(s) that support the development of scientific communication platforms – Total benchmark class
    • Medical group(s) that support the development of scientific communication platforms – Mid-small companies vs. Large companies
    • Functional involvement in the approval of scientific communication platforms – Total benchmark class
    • Functional involvement in the approval of scientific communication platforms – Mid-small companies vs. Large companies
    • Timing for initial development of SCPs – Total benchmark class
    • Timing for initial development of SCPs – Mid-small companies vs. Large companies
    • Frequency of SCP development within benchmarked companies – Total benchmark class
    • Frequency of SCP development within benchmarked companies – Mid-small companies vs. Large companies

    II. SCP Format, Location and Updating

    • SCP format utilized by benchmark Medical teams – Total benchmark class
    • SCP format utilized by benchmark Medical teams – Mid-small companies vs. Large companies
    • Location of scientific communication platforms within benchmark companies – Total benchmark class
    • Location of scientific communication platforms within benchmark companies – Mid-small companies vs. Large companies
    • Desired information in the SCP – Total benchmark class
    • Desired information in the SCP – Mid-small companies vs. Large companies
    • Timing of SCP updates – Total benchmark class
    • Timing of SCP updates – Mid-small companies vs. Large companies

    III. SCP Effectiveness and Faults

    • Effectiveness of scientific communication platforms – Total benchmark class
    • Effectiveness of scientific communication platforms – Mid-small companies vs. Large companies
    • Shortcomings of SCPs within benchmark companies

    IV. SCP Operations

    • Medical group that leads SCP maintenance – Total benchmark class
    • Medical group that leads SCP maintenance – Mid-small companies vs. Large companies
    • Presence of a dedicated Medical SCP Operations position within benchmark companies – Total benchmark class
    • Presence of a dedicated Medical SCP Operations position within benchmark companies – Mid-small companies vs. Large companies

    V. SCP Access and Utilization

    • Functions with access to scientific communication platforms – Total benchmark class
    • Functions with access to scientific communication platforms – Mid-small companies vs. Large companies
    • Metrics used to measure the internal access of SCPs – Total benchmark class
    • Metrics used to measure the internal access of SCPs – Mid-small companies vs. Large companies
    • Assessing the utilization of scientific communication platforms internally – Total benchmark class
    • Assessing the utilization of scientific communication platforms internally – Mid-small companies vs. Large companies

    VI. SCP Best Practices and Pitfalls

    • Interview narrative around scientific communications platforms being the key foundation for effective communication
    • Top strategies recommended for successful SCP implementation
    • Pitfalls observed during SCP initiation/development